Association of respiratory symptoms and lung function with occupation in the multinational Burden of Obstructive Lung Disease (BOLD) study

Background Chronic obstructive pulmonary disease has been associated with exposures in the workplace. We aimed to assess the association of respiratory symptoms and lung function with occupation in the Burden of Obstructive Lung Disease study. Methods We analysed cross-sectional data from 28 823 adults (≥40 years) in 34 countries. We considered 11 occupations and grouped them by likelihood of exposure to organic dusts, inorganic dusts and fumes. The association of chronic cough, chronic phlegm, wheeze, dyspnoea, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1)/FVC with occupation was assessed, per study site, using multivariable regression. These estimates were then meta-analysed. Sensitivity analyses explored differences between sexes and gross national income. Results Overall, working in settings with potentially high exposure to dusts or fumes was associated with respiratory symptoms but not lung function differences. The most common occupation was farming. Compared to people not working in any of the 11 considered occupations, those who were farmers for ≥20 years were more likely to have chronic cough (OR 1.52, 95% CI 1.19–1.94), wheeze (OR 1.37, 95% CI 1.16–1.63) and dyspnoea (OR 1.83, 95% CI 1.53–2.20), but not lower FVC (β=0.02 L, 95% CI −0.02–0.06 L) or lower FEV1/FVC (β=0.04%, 95% CI −0.49–0.58%). Some findings differed by sex and gross national income. Conclusion At a population level, the occupational exposures considered in this study do not appear to be major determinants of differences in lung function, although they are associated with more respiratory symptoms. Because not all work settings were included in this study, respiratory surveillance should still be encouraged among high-risk dusty and fume job workers, especially in low- and middle-income countries.publishedVersio

Cohort Profile: Burden of Obstructive Lung Disease (BOLD) study

The Burden of Obstructive Lung Disease (BOLD) study was established to assess the prevalence of chronic airflow obstruction, a key characteristic of chronic obstructive pulmonary disease, and its risk factors in adults (≥40 years) from general populations across the world. The baseline study was conducted between 2003 and 2016, in 41 sites across Africa, Asia, Europe, North America, the Caribbean and Oceania, and collected high-quality pre- and post-bronchodilator spirometry from 28 828 participants. The follow-up study was conducted between 2019 and 2021, in 18 sites across Africa, Asia, Europe and the Caribbean. At baseline, there were in these sites 12 502 participants with high-quality spirometry. A total of 6452 were followed up, with 5936 completing the study core questionnaire. Of these, 4044 also provided high-quality pre- and post-bronchodilator spirometry. On both occasions, the core questionnaire covered information on respiratory symptoms, doctor diagnoses, health care use, medication use and ealth status, as well as potential risk factors. Information on occupation, environmental exposures and diet was also collected

Huge bilaterally cavitary and nodulary lung lesions: Pulmonary lenfomatoid granulomatosis

WOS: 000209370403867

Myotonik distrofi tip 1'de pulmoner ve kognitif fonksiyonların ilişkisi: bir ön çal

Purpose: We aim to evaluate the correlation of neurocognitive findings with pulmonary functions in Myotonic dystrophy type 1 (DM1). Materials and Methods: This is an observational prospective (between 2013-2015 years) cross-sectional single center study at Neurology and Chest clinics of Cukurova University. Mini mental state examination, forward and backward digit span, verbal fluency (semantic and lexical), clock drawing, verbal and visual memory, pulmonar function tests, arterial blood gas samples were performed to DM1 patients and control group. The presence of correlation between neurocognitive tests and pulmonary function, arterial blood gas samples were researched in DM1. Results: There were significant differences between DM1 (10 male, 14 female) and control group (12 male, 9 female) on verbal fluency, clock drawing, forward and backward digit span tests. There was a positive correlation (p<0.05) between verbal fluency and respiratory function tests (total lung capacity) in DM1. Conclusion: In the present study; we encountered a positive correlation between total lung capacity and verbal fluency in DM1. Pulmonary function tests and neurocognitive assessment should be performed concomitantly in DM1 patients. This provides early detection and treatment of cognitive impairment and loss of pulmonary functions.Amaç: Bu çalışmada myotonik distrofi tip 1 (DM1) olgularında kognitif bulgular ile pulmoner fonksiyonların ilişkisinin incelenmesi amaçlanmıştır. Gereç ve Yöntem: Bu çalışma 2013-2015 yılları arasında Çukurova Üniversitesi Nöroloji ve Göğüs Hastalıkları kliniklerinde prospektif olarak yapılmıştır. DM1 olguları ve sağlıklı kontrol grubunda minimental durum testi, sayı menzili testi, sözel akıcılık (semantik ve leksikal), saat çizme testi, sözel ve görsel bellek testleri, solunum fonksiyon testi, arteriel kan gazı değerlendirilmiştir. Çalışma grupları arasında kognitif testler ile pulmoner fonksiyonlar arası ilişki incelenmiştir. Bulgular: DM1 (10 erkek,14 kadın) ve kontrol grubu (12 erkek, 9 kadın) arasında sözel akıcılık, saat çizme testi, sayı menzili testlerinde anlamlı farklılık saptanmıştır. Ayrıca DM1 olgularında total akciğer kapasitesi ve sözel akıcılık arasında pozitif korelasyon gözlenmiştir (p<0.05). Sonuç: Bu çalışmada DM1 olgularında total akciğer kapasitesi ve sözel akıcılık arasında pozitif korelasyon gözlenmiştir. DM1 olgularında pulmoner ve kognitif fonksiyonların korele olması, bu fonksiyonların birlikte değerlendirilmesi gerekliliğini ortaya çıkarmaktadır. Böylece erken tanı ve tedavi mümkün olacaktı

CAN PET-CT BE A PROGNOSTIC FACTOR IN PATIENTS WITH NON-SMALL CELL LUNG CANCER?

WOS: 000291769800325

Asthma and vitamin D

WOS: 000449650901585

A Tuberculosis pleuresia mimicking cardiomegaly

WOS: 000251886600242

Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNF alpha

WOS: 000249813700012PubMed ID: 17332973In this study, we investigated the safety and toxicity of isoniazid (INH) intervention therapy to the patients with latent tuberculosis who were given tumor necrosis factor alpha (TNF alpha) for the treatment of their rheumatologic diseases. In this prospective clinical study, we enrolled 86 patients receiving anti-TNF alpha therapy for their rheumatologic diseases between April 2005 and September 2006. Of all the subjects, 45 had rheumatoid arthritis, 36 had ankylosing spondylitis, and 5 had psoriatic arthritis. In addition to anti-TNF alpha therapy, 60 of the 86 patients were given INH intervention for revealed latent tuberculosis. INH at a dosage of 300 mg daily was given for 9 months. Hepatotoxicity due to the INH therapy was considered when the serum alanine aminotransferase (ALT) and/or aspartate aminotransaminase (AST) levels showed at least threefold increase with respect to their baseline serum levels. Serum ALT and AST levels were measured by enzymatic colorimetric method in fasting peripheral blood samples at 0 (baseline), 1, 2, 3, 6, and 9 months. Of 86 patients, 47 (54.7%) were women (mean age +/- SD, 44.+/- 10.9 years) and 39 (45.3%) were men (38.8 +/- 10.1 years). Except five patients (8.3%), liver toxicity due to the INH therapy was not encountered among the patients, and after temporarily discontinuing the INH therapy of these five subjects, serum transaminase levels returned to the normal ranges. No hepatotoxicity was observed in the non-INH group. However, there was no statistical significance between INH-treated and non-INH-treated group (p=0.317). In addition, none of the 86 patients developed active tuberculosis infection during the treatment period. In conclusion, for those patients who were assigned to the TNF alpha treatment for their rheumatologic disorders and carrying risk for latent tuberculosis, INH intervention therapy was found to be safe and efficacious

Massive Pulmonary Thromboembolism In A Sarcoidosis Patient: Case Report

Although sarcoidosis is not a well known risk factor of pulmonary thromboembolism, recent investigations shows increased risk of pulmonary thromboembolism in these patients with the lack of any other risk factor. In this case report, massive pulmonary embolism was presented in a forty seven years old female patient who is followed up under metilprednisolon therapy due to sarcoidosis for five months. This patient was underlined because of that sarcoidosis may be a potential risk factor of pulmonary thromboembolism and must be kept in mind at the patients with sarcoidosis and acute deletoration. Keywords: [Cukurova Med J 2011; 36(1.000): 37-40